We know how companies can and should be built. Founded in 2017, Qiming Venture Partners USA is a healthcare venture capital firm and healthcare investor with a combination of deep technical expertise that allows us to identify tomorrow’s innovations early and strong operational experience with a hands-on approach that makes us the investor of choice for early-stage biotech companies. Our partners often are sought-after to be on company boards because of their proven, hands-on approach to supporting CEOs and scaling operations. They are trusted business and thought partners. All of our partners have worked and lived outside of the US, providing us with a true global mindset and our networks are extensive. Only Qiming Venture Partners USA can offer exclusive access and synergy to China, the second-largest healthcare market in the world. We have a unique ability to leverage a world-class China and broader Asian network for market diligence, deal flow, and operational support for portfolio companies. We harness the deep and highly accretive backgrounds and skillsets of our founders with a next-generation approach through our partners to understand tomorrow’s innovations and reaching across a wide variety of crossover and public investors.
External link for Qiming Venture Partners USA
Seattle, Washington 98121, US
Cambridge, Massachusetts 02142, US
San Francisco, California 94022, US
Qiming Venture Partners USA reposted this
Exciting partnership from Soda Health!
Soda Health is proud to announce our game changing partnership with Hy-Vee, Inc.. Together, Soda Health and Hy-Vee are reducing food insecurity and improving overall health outcomes to millions of midwesterners served by Hy-Vee’s network of more than 275 retail pharmacies. We are privileged to partner with Aaron Wiese, Angie Nelson, and the exceptional team at Hy-Vee.
Qiming Venture Partners USA reposted this
Congratulations to Umoja Biopharma on their groundbreaking partnership with AbbVie to advance development of in vivo CAR-T therapies for patients in need. Umoja's VivoVec + RACR/CAR technology enables CAR-T transduction to occur directly in the patient while avoiding challenging chemotherapeutic lymphodepletion regimens, overcoming sizable patient access + manufacturing challenges faced with autologous CAR-T therapies, which are created outside the body. Today, we are one significant step closer to a world where more patients, in a safer manner, could be eligible to receive potentially disease-curative medicines. This is made possible by Umoja's outstanding drug development expertise and catalyzed by their state of the art manufacturing capabilities at the CLIMB.
Hearty congrats to the Icosavax, Inc. team on positive data for bivalent RSV / hMPV vaccine and subsequent transaction to AstraZeneca! https://lnkd.in/gv_x9cZU